Reviewing Immunomedics (IMMU) and Its Rivals
Immunomedics (NASDAQ: IMMU) is one of 186 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Immunomedics to related businesses based on the strength of its institutional ownership, analyst recommendations, profitability, valuation, risk, dividends and earnings.
Insider and Institutional Ownership
76.3% of Immunomedics shares are owned by institutional investors. Comparatively, 49.3% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 6.6% of Immunomedics shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Immunomedics has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Immunomedics’ peers have a beta of 1.57, indicating that their average share price is 57% more volatile than the S&P 500.
Earnings & Valuation
This table compares Immunomedics and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Immunomedics||$3.09 million||-$153.20 million||-5.41|
|Immunomedics Competitors||$217.29 million||-$39.39 million||-106.45|
Immunomedics’ peers have higher revenue and earnings than Immunomedics. Immunomedics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares Immunomedics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations for Immunomedics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Immunomedics currently has a consensus target price of $15.50, suggesting a potential upside of 27.89%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 36.55%. Given Immunomedics’ peers higher possible upside, analysts plainly believe Immunomedics has less favorable growth aspects than its peers.
Immunomedics peers beat Immunomedics on 8 of the 12 factors compared.
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.